Previous 10 | Next 10 |
FLORHAM PARK, N.J., June 03, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techn...
ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...
Gainers: Washington Prime (WPG) +99%.Orbital Energy (OEG) +67%.Vertex Energy (VTNR) +28%.LexinFintech (LX) +28%.ENGlobal (ENG) +28%.New Concept Energy (GBR) +26%.Cloudera (CLDR) +24%.Aethlon Medical (AEMD) +24%.Aesthetic Medical International (AIH) +22%.Lineage Cell Therapeutics (LCTX) +...
FLORHAM PARK, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced it will h...
PDS Biotechnology Corporation (NASDAQ:PDSB) traded at a new 52-week high today of $12.46. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 2 million shares. In the past 52 weeks, PDS Biotechnology Corporation share prices are bra...
Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded at a new 52-week high today of $10.85. This new high was reached on above average trading volume as 4 million shares traded hands, while the average 30-day volume is approximately 2 million shares. PDS Biotechnology Corporation...
PDS Biotechnology (PDSB) and the Head and Neck Cancer Alliance announce a new partnership to raise awareness of new and developing treatment options for patients with HPV-attributed head and neck cancer diagnoses.PDS's lead candidate, PDS0101, uses versamune to activate the immune system...
FLORHAM PARK, N.J., May 27, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a novel therapy for HPV-associated cancer based on the Company’s proprietary Versamune® T-cell activating technology, and the Head...
PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at a new 52-week high of $9.56. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 2 million shares. Over the past year, PDS Biotechnology Corporation has traded in a range o...
Shares of PDS Biotechnology Corporation (NASDAQ:PDSB) traded today at $8.82, eclipsing its 52-week high. So far today approximately 4 million shares have been exchanged, as compared to an average 30-day volume of 562,000 shares. In the past 52 weeks, shares of PDS Biotechnology Corporati...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...